Summit Therapeutics Inc. Increase (Decrease) in Other Current Liabilities
Summit Therapeutics Inc. (SMMT) reported Increase (Decrease) in Other Current Liabilities of $339.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentLiabilities · last filed 2026-07-23
- Summit Therapeutics Inc. increase (decrease) in other current liabilities for the quarter ending 2026-06-30 was $1.47M, a 109.38% increase year-over-year.
- Summit Therapeutics Inc. increase (decrease) in other current liabilities for the quarter ending 2026-03-31 was -$1.14M.
- Summit Therapeutics Inc. increase (decrease) in other current liabilities for the quarter ending 2025-09-30 was $476.00K, a 135.64% increase year-over-year.
- Summit Therapeutics Inc. increase (decrease) in other current liabilities for the quarter ending 2025-06-30 was $704.00K.
| Period end | Increase (Decrease) in Other Current Liabilities 3 month | Increase (Decrease) in Other Current Liabilities 6 month | Increase (Decrease) in Other Current Liabilities 9 month |
|---|---|---|---|
| 2026-06-30 | $1.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $339.00K 10-Q · filed 2026-07-23 | |
| 2026-03-31 | -$1.14M 10-Q · filed 2026-04-30 | ||
| 2025-09-30 | $476.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-20 | $1.18M derived: sum of 2 quarters · filed 2026-07-23 | $134.00K 10-Q · filed 2025-10-20 |
| 2025-06-30 | $704.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | -$342.00K 10-Q · filed 2026-07-23 | |
| 2025-03-31 | -$1.05M 10-Q · filed 2026-04-30 | ||
| 2024-09-30 | $202.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-20 | $197.00K derived: sum of 2 quarters · filed 2025-10-20 | $294.00K 10-Q · filed 2025-10-20 |
| 2024-06-30 | -$5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $92.00K 10-Q · filed 2025-08-11 | |
| 2024-03-31 | $97.00K 10-Q · filed 2025-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |